Immutep has initiated an investigator-initiated Phase II trial of eftilagimod alfa (efti) as a neoadjuvant therapy in early-stage HR+/HER2-negative breast cancer, led by the George Washington University Cancer Center. The single-arm, two-stage study will enroll up to 50 evaluable patients eligible for neoadjuvant chemotherapy and will test subcutaneous efti as three weeks of monotherapy followed by combination with standard neoadjuvant chemotherapy before surgery. Pathologic complete response is the primary endpoint. The trial is primarily grant-funded, with Immutep supplying the drug, technical support, and limited budgeted funding.
The strategic question is whether an antigen-presenting cell agonist can shift the immunologic cold-start of HR+/HER2-negative disease, where checkpoint inhibitors have produced only modest and variable gains in the neoadjuvant setting. The mechanism matters: efti is a soluble LAG-3 protein and MHC class II agonist designed to broadly activate antigen-presenting cells and downstream T-cell and innate effectors, potentially amplifying chemotherapy-released tumor antigens in vivo. If that translates into meaningful pathologic and longer-term outcomes, it could open a distinct immunotherapy path in a subtype historically less responsive to PD-1/PD-L1 blockade.
For oncologists and patients, the appeal is a potentially safe, combination-friendly, subcutaneous immunotherapy that could improve response without adding substantial toxicity. Yet in HR+ early breast cancer, pathologic complete response is an imperfect surrogate for long-term benefit. Regulators and payers increasingly require event-free survival or validated molecular surrogates such as ctDNA clearance to support broad adoption, particularly in a population already navigating complex adjuvant choices that include endocrine therapy and expanding CDK4/6 inhibitor use. Clinical teams will look for signals beyond pCR, including immune signatures, MHC class II expression, tumor-infiltrating lymphocytes, and inflammatory cytokine profiles to identify who benefits and when to sequence therapy.
Commercially, the neoadjuvant chemo-treated HR+/HER2-negative segment is focused on higher-risk patients, which constrains initial market size but offers a pragmatic foothold for proof-building. If results are encouraging, the next hurdle will be a randomized study powered for event-free survival and potentially biomarker-enriched cohorts. Pricing and access will depend on demonstrating an additive benefit over chemotherapy with a defensible budget impact, a bar raised by increasing payer scrutiny of perioperative immuno-oncology in indications with strong existing standards of care. The IIT structure and grant funding highlight a broader biotech pattern: extending into earlier lines through academically led trials to conserve cash while generating signals that can catalyze partnerships or non-dilutive financing.
For competitors, the move underscores a shift in immuno-oncology exploration toward antigen presentation and innate-adaptive cross talk, not just checkpoint inhibition. The LAG-3 category is bifurcating between antagonists paired with PD-1 and agents like efti that activate APCs; positive neoadjuvant data would validate the latter’s distinct role and could accelerate combination strategies across solid tumors. For Medical Affairs, this is a canvas for data generation on immune activation kinetics, perioperative safety, and real-world implementation, as well as education for surgeons and medical oncologists on integrating immunotherapy into existing neoadjuvant workflows.
The signal to watch is not only whether efti improves pCR, but whether that translates into sustained event-free survival and molecular clearance in high-risk HR+/HER2-negative patients. If an APC agonist reliably converts chemo-induced antigen release into durable immunity, the neoadjuvant immunotherapy playbook in hormone receptor–positive disease could change quickly; if not, the field may double down on biomarker-driven, chemo-sparing strategies.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
